R&D channel feed – Endpoints News

R&D channel feed

Ideaya outlines regulatory path for rare eye cancer drug after positive mid-stage data

7 months ago

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

7 months ago

Regulatory RNA startup CAMP4 files for IPO as more biotechs line up listings

7 months ago

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

7 months ago

Novo axes Phase 2 of Forma-acquired drug in myelodysplastic syndromes

7 months ago

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

7 months ago

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

7 months ago

Edgewise’s stock surges as heart drug passes early safety test

7 months ago

4DMT's gene therapy reduced need for standard-of-care injections to treat age-associated vision loss

7 months ago

Keytruda adds new FDA approval for a rare form of mesothelioma

7 months ago

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

7 months ago

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists triggered a revolution

7 months ago

Conducting trials via routine clinical practice: FDA explains how in new draft guidance

7 months ago

Sun, surprises and new summits at Europe’s biggest cancer conference

7 months ago

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

7 months ago

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

7 months ago

Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration

7 months ago

Emmet Stephenson gives $150M to City of Hope for pancreatic cancer, creating million-dollar research prize

7 months ago

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

7 months ago

FDA tells oncology companies how to run multi-regional cancer trials with a US approval in mind

7 months ago

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

7 months ago

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

7 months ago

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

7 months ago

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

7 months ago

First page Previous page 24 25 262728 29 30 Next page Last page